REG - BiVictriX Therapcts. - Pipeline update on BVX002

Bivictrix TherapeuticsAnnouncement

30/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd1963Va&default-theme=true

RNS Number : 1963V  BiVictriX Therapeutics PLC  30 November 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

 

Pipeline update on lead solid tumour programme, BVX002

 

·   Emerging data identifies ovarian cancer as one of the lead indications
for BVX002, BiVictriX's first-in-class Antibody Drug Conjugate (ADC) targeting
solid tumour indications

·   Final antibody sequences selected for BVX002 drug candidate, Company on
track to identify development lead in 2024

·   An updated version of BiVictriX's corporate presentation is now
available on the Company's website

 

Alderley Park, 30 November 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a differentiated approach to develop
novel, next-generation anti-cancer precision Antibody Drug Conjugates,
offering substantially improved cancer cell selectivity and therapeutic
activity, announces that the final sequences have been selected for the
Company's second programme, BVX002, targeting solid tumour indications, with a
lead indication in ovarian cancer.

 

These final antibody sequences, selected from the panel identified earlier
this year, showed strong efficacy and selectivity towards targeted cancer
cells as compared to non-target cells and passed early assessments of
developability.

 

In addition, emerging data from primary patient samples using a combination of
next generation sequencing techniques and laboratory-based profiling has
generated initial results which suggest that the antigen fingerprint targeted
by BVX002 is present in multiple solid tumour indications, with especially
high prevalence in high-grade serous ovarian cancer (expressed in >86% of
ovarian cancer patient samples), representing a disease of significant unmet
need and commercial potential for BVX002.

 

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, said:
"ADCs have demonstrated incredible promise as an alternative therapeutic
option to current monotherapies and combination therapies across
difficult-to-treat cancers, backed by high specificity, versatility and
selectivity. We have been encouraged by BiVictriX's progress to date in our
lead BVX001 programme for the treatment of Acute Myeloid Leukaemia and are
also pleased by the further development and expansion of our proprietary ADC
pipeline, where BVX002 is showing early promise in targeting high-grade serous
ovarian carcinoma, which accounts for 75% of epithelial ovarian cancers. We
expect to identify a lead development candidate for BVX002 in 2024 and look
forward to providing our shareholders with further updates as appropriate."

 

Corporate Presentation

An updated version of BiVictriX's corporate presentation reflecting the recent
progress made across the BVX001 and BVX002 programmes, as well as the
Company's strengthened IP position, is now available on the Company's website
(https://bivictrix.com/investor-relations/) .

 

 ENDS

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)      Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)             Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 ICR Consilium
 Mary-Jane Elliott, Namrata Taak,                     Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific
Bi-Cygni® fingerprints, which enable the Company to target a diverse array of
different cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug Conjugate
therapeutic design, to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and areas of high
unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQBLBXXFLFFBB